Daurisoline Inhibits Lung Cancer Growth by Targeting Glycolysis
Author Information
Author(s): S.-M. Tan, Luo Lan, He Yi-Fu, Li Wei, Wan Xin-Xing
Primary Institution: The Third Xiangya Hospital, Central South University, Changsha, China
Hypothesis
Daurisoline can suppress lung cancer growth by regulating the AKT-GSK3β-HK axis that governs lactate production in the tumor microenvironment.
Conclusion
Daurisoline shows potential as an anti-tumor agent by inhibiting glycolysis and reducing lung cancer progression.
Supporting Evidence
- Daurisoline decreased glucose consumption and lactate production in lung cancer cells.
- Daurisoline inhibited the expression of HK2, a key enzyme in glycolysis.
- Animal studies showed that Daurisoline reduced tumor volume and weight without significant side effects.
- Daurisoline directly binds to AKT and inhibits its phosphorylation.
Takeaway
Daurisoline is a natural compound that helps fight lung cancer by stopping cancer cells from using sugar for energy.
Methodology
The study involved in vitro assays on lung cancer cell lines and in vivo experiments on nude mice to assess the effects of Daurisoline on tumor growth and glycolysis.
Limitations
The exact mechanism of Daurisoline's action remains unclear and requires further investigation.
Participant Demographics
Nude mice were used in the in vivo studies.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website